Delfi Diagnostics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically validated FirstLook Lung test; partnering with Hackensack Meridian Health in 2025;
About
Delfi Diagnostics is a biotechnology company founded in 2019 by Victor Velculescu and headquartered in Baltimore, Maryland, specializing in blood-based cancer detection using machine learning and whole-genome sequencing of cell-free DNA (cfDNA). The company''s AI platform analyzes genome-wide fragmentation patterns of cell-free DNA from a simple blood draw — a liquid biopsy — to detect cancer-associated signals across multiple cancer types. This approach, called DELFI (DNA Evaluation of Fragments for Early Interception), generates a large number of features across the entire genome that machine learning models synthesize into a cancer risk score.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.